This discussion paper addresses the safety of HIV cure studies, particularly those involving stopping antiretroviral therapy, known as an analytic treatment interruption (ATI) in the context of the SARS-CoV-2 pandemic. More than 30 studies listed on ClinicalTrials.gov include an ATI and many others were planned to begin over the next 12 months but most were halted due to the COVID-19 pandemic. We consider the ethics, risks and practical considerations to be taken into account before re-opening HIV cure clinical trials, noting the specific risks of ATI in the context of circulating SARS-CoV-2.

Original publication

DOI

10.1016/j.jve.2020.100025

Type

Journal article

Journal

Journal of virus eradication

Publication Date

06/12/2020

Addresses

Department of infectious disease, Imperial College London and Imperial College NIHR BRC, London, UK.